Free Trial

Deciphera Pharmaceuticals (DCPH) News Today

$25.59
0.00 (0.00%)
(As of 06/17/2024 ET)
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Sold by Parkman Healthcare Partners LLC
Parkman Healthcare Partners LLC reduced its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 561,025 shares of the co
Deciphera Pharmaceuticals logo with Medical background
Braidwell LP Has $18.86 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Braidwell LP cut its position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 64.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,169,490 shares of the company's stock after selling 2,166,731 shares duri
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Nebula Research & Development LLC
Nebula Research & Development LLC boosted its position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 93.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,159 shares of the
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $25.59
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.59
Deciphera Pharmaceuticals logo with Medical background
New Leaf Venture Partners L.L.C. Sells 632,596 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
New Leaf Venture Partners L.L.C. reduced its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 52.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 576,975 shares of the company's stock a
Deciphera Pharmaceuticals logo with Medical background
50,735 Shares in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Acquired by Campbell & CO Investment Adviser LLC
Campbell & CO Investment Adviser LLC bought a new position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 50,735 shares of the company's stock, valued at approximately $818,000. Campbell & CO In
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Armistice Capital LLC
Armistice Capital LLC raised its stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,200,000 shares of the company's stock after ac
Deciphera Pharmaceuticals logo with Medical background
Dimensional Fund Advisors LP Raises Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Dimensional Fund Advisors LP raised its holdings in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,561,654 sha
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 52-Week High at $25.55
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sets New 1-Year High at $25.55
Deciphera Pharmaceuticals logo with Medical background
BNP Paribas Financial Markets Boosts Stock Holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
BNP Paribas Financial Markets boosted its stake in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 118.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,653 shares of th
Deciphera Pharmaceuticals logo with Medical background
Trexquant Investment LP Takes $2.19 Million Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Trexquant Investment LP acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,994 shares of the company's stock,
Deciphera Pharmaceuticals logo with Medical background
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Average Recommendation of "Hold" from Brokerages
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and three have g
Deciphera Pharmaceuticals logo with Medical background
Jump Financial LLC Takes $522,000 Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jump Financial LLC purchased a new position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 32,375 shares of the company's sto
Deciphera Pharmaceuticals logo with Medical background
Panagora Asset Management Inc. Acquires 144,097 Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Panagora Asset Management Inc. grew its holdings in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) by 157.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 235,845 shares of the company's
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Strong Trading Volume
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading Volume
Deciphera Pharmaceuticals logo with Medical background
Fisher Asset Management LLC Acquires New Position in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Fisher Asset Management LLC acquired a new stake in Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 62,372 shares of the company's stock, v
Deciphera Pharmaceuticals (NASDAQ:DCPH) Cut to Market Perform at Leerink Partnrs
Leerink Partnrs cut Deciphera Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Short Interest Down 5.1% in April
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,750,000 shares, a drop of 5.1% from the March 31st total of 6,060,000 shares. Approximately 11.5% of the company's shares are sold short. Based on an average daily trading volume, of 525,500 shares, the days-to-cover ratio is presently 10.9 days.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Large Volume Increase
Deciphera Pharmaceuticals (NASDAQ:DCPH) Sees Unusually-High Trading Volume
Deciphera Pharmaceuticals (NASDAQ:DCPH) Earns "Neutral" Rating from Guggenheim
Guggenheim reiterated a "neutral" rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Rating Increased to Equal Weight at Barclays
Barclays raised shares of Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price target for the stock from $9.00 to $26.00 in a research report on Tuesday.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH - Get Free Report) has earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have assigned a b
Jefferies Financial Group Reaffirms Hold Rating for Deciphera Pharmaceuticals (NASDAQ:DCPH)
Jefferies Financial Group restated a "hold" rating and issued a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday.
Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 52-Week High at $25.03
Deciphera Pharmaceuticals (NASDAQ:DCPH) Reaches New 12-Month High at $25.03
Get Deciphera Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

The ONE AI Stock to own now. (It’s not Nvidia.) (Ad)

Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …

Click here to see the presentation now.

DCPH Media Mentions By Week

DCPH Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

DCPH
News Sentiment

1.32

0.91

Average
Medical
News Sentiment

DCPH News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

DCPH Articles
This Week

5

3

DCPH Articles
Average Week

Get Deciphera Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:DCPH) was last updated on 6/18/2024 by MarketBeat.com Staff

From Our Partners